69807-82-5

Basic information

• Product Name: 1H-1,2,4-Triazole-1-propanamine
• Synonyms: 1H-1,2,4-Triazole-1-propanamine;3-(1H-1,2,4-triazol-1-yl)propan-1-amine hydrochloride;3-(1H-1,2,4-triazol-1-yl)propan-1-amine(SALTDATA: 2HCl);[3-(1H-1,2,4-triazol-1-yl)propyl]aMine dihydrochloride (SALTDATA: 2HCl)
• CAS NO: 69807-82-5
• Molecular Formula: C₅H₁₀N₄
• Molecular Weight: 126.1597
• Mol File: 69807-82-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 271.5°C at 760 mmHg
• Flash Point: 118°C
• Appearance: /
• Density: 1.24g/cm³
• Vapor Pressure: 0.00644mmHg at 25°C
• Refractive Index: 1.608
• CAS DataBase Reference: 1H-1,2,4-Triazole-1-propanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-1,2,4-Triazole-1-propanamine(69807-82-5)
• EPA Substance Registry System: 1H-1,2,4-Triazole-1-propanamine(69807-82-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 69807-82-5(Hazardous Substances Data)

Usage

General Description

1H-1,2,4-Triazole-1-propanamine is a type of chemical compound that belongs to the class of organic compounds known as 1,2,4-triazoles. These are organic compounds that contain a 1,2,4-triazole ring made up of two carbon atoms and three nitrogen atoms. It may also be referred to as 1-(3-aminopropyl)-1H-1,2,4-triazole. It is involved in a variety of chemical reactions, and as such, it is commonly used in chemical synthesis procedures. The specific properties of 1H-1,2,4-Triazole-1-propanamine can vary based on the presence of different functional groups and can be altered through synthetic modifications.

InChI:InChI=1/C5H10N4/c6-2-1-3-9-5-7-4-8-9/h4-5H,1-3,6H2

Upstream product

• 288-88-0 1,2,4-Triazole 
• 1336-21-6 ammonium hydroxide 
• 107-13-1 acrylonitrile 
• 83948-53-2 3-bromopropylamine tert-butylcarbamate 
• 76686-83-4 3-(1H-1,2,4-triazole-1-yl)propanenitrile 
• 101225-88-1 N-(3-[1,2,4]triazol-1-yl-propyl)-phthalimide 

Downstream Products

• 100468-01-7 2-Carboxy-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide 
• 100468-13-1 2-(4-Chloro-phenoxy)-N-(3-[1,2,4]triazol-1-yl-propyl)-acetamide 
• 100468-14-2 (E)-3-(4-Chloro-phenyl)-N-(3-[1,2,4]triazol-1-yl-propyl)-acrylamide 
• 100467-99-0 Biphenyl-2-carboxylic acid (3-[1,2,4]triazol-1-yl-propyl)-amide 
• 100467-95-6 4-Benzoyl-N-(3-[1,2,4]triazol-1-yl-propyl)-benzamide 
• 100467-90-1 3-bromo-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide 
• 100468-27-7 2-(3-Chloro-phenyl)-N-(3-[1,2,4]triazol-1-yl-propyl)-acetamide 
• 100468-26-6 N-(3-[1,2,4]Triazol-1-yl-propyl)-3-trifluoromethyl-benzamide 
• 100467-93-4 4-Butoxy-N-(3-[1,2,4]triazol-1-yl-propyl)-benzamide 
• 100467-89-8 4-fluoro-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide 
• 100467-85-4 3-chloro-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide 
• 100467-97-8 4(dimethylamino)-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide 
• 100467-96-7 4-Acetylamino-N-(3-[1,2,4]triazol-1-yl-propyl)-benzamide 
• 100467-83-2 N-(3-[1,2,4]Triazol-1-yl-propyl)-benzamide 

Relevant articles and documents

Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery

Using structure-guided design, several cell based assays, and microdosed positron emission tomography (PET) imaging, we identified a series of highly potent, selective, and brain-penetrant oxazole-4-carboxamide-based inhibitors of glycogen synthase kinase-3 (GSK-3). An isotopologue of our first-generation lead, [3H]PF-367, demonstrates selective and specific target engagement in vitro, irrespective of the activation state. We discovered substantial ubiquitous GSK-3-specific radioligand binding in Tg2576 Alzheimer's disease (AD), suggesting application for these compounds in AD diagnosis and identified [11C]OCM-44 as our lead GSK-3 radiotracer, with optimized brain uptake by PET imaging in nonhuman primates. GSK-3β-isozyme selectivity was assessed to reveal OCM-51, the most potent (IC50 = 0.030 nM) and selective (>10-fold GSK-3β/GSK-3α) GSK-3β inhibitor known to date. Inhibition of CRMP2T514 and tau phosphorylation, as well as favorable therapeutic window against WNT/β-catenin signaling activation, was observed in cells.

AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS

The present invention is related to azole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such azole derivatives. Said azole derivatives are modulators of the protein kinase signalling pathways, particularly the one involving c-Jun N-terminal kinase and/or Glycogen Kinase Synthase 3. The present invention is furthermore related to novel azole derivatives as well as to methods of their preparation. X is O, S or NR0, with R0 being H or an unsubstituted or substituted C1 -C6 alkyl; A is 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl group.

N-[(1H-1,2,4-Triazol-1-yl)alkyl]-arylamides

N-[(1H-1,2,4-Triazol-l-yl)alkyl]arylamides which are inhibitors of thromboxane synthetase enzyme.